Akebia Therapeutics (AKBA) Posts Q2 Loss of 40c/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. ARM
3. FIS
4. BROS
5. EXPE
6. QCOM
7. CPAY
8. PAYC
9. EW
10. RPD

Go back to Akebia Therapeutics (AKBA) Posts Q2 Loss of 40c/Share

Akebia Announces Second Quarter 2015 Financial Results

August 11, 2015 4:32 PM EDT

-On Track to Release Top Line Data from Vadadustat Phase 2 Study in Dialysis Dependent Patients This Quarter-

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (NASDAQ: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced financial results for the second quarter ended June 30, 2015.

During the second quarter, we presented new data highlighting the best-in-class potential of vadadustat, formerly known as AKB-6548, in renal anemia, strengthened our balance sheet and advanced our pipeline toward key... More